Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TAK-375: Phase II data; Phase III

In a randomized, double-blind U.S. trial in 375 healthy adults, both 16 and 64 mg doses of TAK-375 produced significantly shorter

Read the full 218 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE